China SXT Pharmaceuticals Inc (SXTC) — Cash Flow-to-Debt Ratio
China SXT Pharmaceuticals Inc (SXTC) has a Cash Flow-to-Debt Ratio of -0.45x as of June 2026, meaning its operating cash flow of $-2.26 Million could theoretically repay 0% of its total liabilities ($5.05 Million) in one year. See SXTC FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
China SXT Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2016–2026)
Historical debt coverage capacity for China SXT Pharmaceuticals Inc across 11 annual periods. For the full cash flow conversion analysis, see China SXT Pharmaceuticals Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for China SXT Pharmaceuticals Inc (2016–2026)
Year-by-year debt coverage analysis for China SXT Pharmaceuticals Inc. Check China SXT Pharmaceuticals Inc (SXTC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -0.80x | $-4.02 Million | $5.05 Million | ▼ -111.2% |
| 2025 | -0.38x | $-2.35 Million | $6.22 Million | ▼ -79.7% |
| 2024 | -0.21x | $-1.93 Million | $9.20 Million | ▼ -3758.4% |
| 2023 | -0.01x | $-80.76K | $14.86 Million | ▲ +96.1% |
| 2022 | -0.14x | $-2.37 Million | $17.12 Million | ▼ -95.8% |
| 2021 | -0.07x | $-1.32 Million | $18.59 Million | ▼ -193.3% |
| 2020 | 0.08x | $934.25K | $12.30 Million | ▲ +102.0% |
| 2019 | 0.04x | $239.19K | $6.36 Million | ▼ -91.4% |
| 2018 | 0.44x | $1.92 Million | $4.37 Million | ▲ +436.4% |
| 2017 | 0.08x | $293.04K | $3.58 Million | ▲ +149.2% |
| 2016 | 0.03x | $182.47K | $5.55 Million | — |